(RTTNews) – Nevro Corp. (NVRO) said that in its patent litigation against Boston Scientific, the corporations had accepted the rejection of Nevro’s patent application in the Northern District of California for high-frequency SCS treatment paresthesia .
Nevro said he had agreed to reject all remaining claims in the California case because Boston Scientific had no plans yet to commercially launch a high-frequency SCS formula in the United States.
Nevro had applied for an initial and permanent court order opposing any additional violations, as well as damages and legal fees. The case is now over, and Nevro received the requested help. There has been no resolution imposing restrictions on existing laws or long-term products, Boston Scientific said in a statement.
Meanwhile, Boston Scientific’s patent infringement and misappropriation of industry secrets that oppose Nevro in Delaware will continue and be affected by the California dispute, Boston Scientific said. But it’s not the first time For the Delaware District.